<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">The safety of JR-141 was evaluated in two patients in a dose-escalation study (part 1). Concentrations of JR-141 in the plasma were detected in a dose-dependent manner and peaked at 3 hr after initiation of administration, because the duration of intravenous infusion was 3 hr (
 <xref rid="fig2" ref-type="fig">Figure 2</xref>A). One patient (H1-01-01) developed erythema after the first infusion (0.01 mg/kg) and during the second (0.1 mg/kg), but the erythema disappeared quickly. The same patient also experienced transient mild pyrexia (37.5°C) after the third dosing (1.0 mg/kg; 
 <xref rid="tbl2" ref-type="table">Table 2</xref>). The other patient (H1-08-01) experienced no adverse reactions.
</p>
